GSDM family and glioma

Abstract

Biomarkers play a central role in diagnosing, prognosis, and therapeutic management of gliomas, a diverse group of malignancies arising from glial cells in the brain and spinal cord. Among the various emerging biomarkers, the gasdermin protein family has attracted attention for its involvement in pyroptosis. Understanding the expression and function of GSDM in gliomas may provide new insights into tumor behavior and new avenues for therapeutic intervention. This review discusses the GSDM family's significance as a glioma biomarker, explores its dual role in tumor suppression, and highlights its potential utility in clinical practice as a novel target for glioma therapy.